483 Response Revance Therapeutics Jul 2021

Carla Lundi FDA, Joao Pedras Vasconcel FDA$119.00 - Available Now

FDA investigators audited the Revance Therapeutics - Nashville, TN, United States facility and issued inspectional observation (via FDA 483) on 02 Jul 2021.

Product details

  • Category:
  • Inspection end: 02 Jul 2021
  • Location: Nashville, United States
  • FEI: 3007772056
Add To Cart